Laboratory for Epigenomics

Laboratory for Epigenomics

left right

The basic scientific interest of this Laboratory is cancer chemoprevention, in the context of reversion of earliest changes of the epigenome (primarily DNA methylation and specific suppressive histone modifications) in a (future, if no intervention was performed) cancer cell.

The experimental work in this Laboratory is based on cell cultures and malignant head and neck tumors, as model systems.

The epigenome research performed on different cancer cell lines includes „the intact system“ and the system that is modified, as a consequence of targeted application of natural compounds (primarily resveratrol and curcumin), as well as poly(ADP-ribosyl)ation inhibitors. The primary focuses of our interest are: CTCF, BORIS, EZH2 i JMJD3 – in the context of aberrant DNA methylation, alternative splicing of pre-mRNA transcripts and establishment of repressive histone H3 marks.

These genes are being investigated in a native clinical models of extirpated malignant head and neck tumors (larynx an hypopharynx), as a part of our collaboration with Clinical Hospital Center „Sisters of Charity“. These samples are, since 2001, an important part of the Tumor Tissue Bank, established at our Division in 1991.

The members of this Laboratory actively participate in various educational activities, including participation in different collegia and teaching classes at the University of Zagreb, University of Split, University of Rijeka and University of Dubrovnik.

Koraljka Gall Trošelj
MD, Ph.D.

Senior Research Associate
+385 1 456 0972
1552

Marko Tomljanović

+385 1 457 1248
1763

Paško Konjevoda
Ph.D.

Research associate
+385 1 468 0193
1334

Renata Novak Kujundžić
D.V.M., Ph.D.

Research Associate
+385 1 456 0949
1343 1714

Višnja Stepanić
Ph.D.

Senior research associate
+385 1 457 1248
1763

Screening for mutations in the ret proto-oncogene

This genetic analysis is indicated in all newly diagnosed medullary thyroid patients in order to exclude or confirm the existance of an inherited mutation. These analyses are based on the contract between  Clinical Hospital Center "Sister of Charity" and Rudjer Boskovic Institute.

more »

PhD Thesis 

Grbeša, Ivana. Abberant DNA methylation and loss ofIGF2/H19genomic imprinting in malignant laryngeal tumors. Zagreb : PMF, 11.06.2010. , Supervisor: Gall Trošelj, Koraljka. 

 

Diploma/Graduation Thesis

 

Rončević, Marina. The effect of curcumin, resveratrol and sirtinol treatment onEZ2Hgene transcription in HT29 cells. Zagreb : PMF, 13.07. 2011., Supervisor: Novak Kujundžić, Renata.

 

Zovkić, Sanja. The IGF2 promoters P0 and P1 activity in differentially methylated two human carcinoma cell lines. Zagreb : PMF, 25.05. 2011., Supervisor: Koraljka Gall-Trošelj.

 

Kolundžija, Sandra. Effect of DNA methylation and CTCF/BORIS binding onIGF2AStranscription in Cal27 and HT29 cells. Zagreb : PMF, 27.09. 2010., 63 str. Supervisor: Novak Kujundžić, Renata.

 

Ćuk, Katarina. Binding of CTCF and BORIS toTOP2Apromoter in CAL 27 cells. Zagreb : PMF, 14.05. 2009., Supervisor: Novak Kujundžić, Renata.

 

Popović, Doris. CTCF protein binding to H19 ICR in CAL 27 cells. Zagreb : PMF, 26.09. 2008.,  Supervisor: Novak Kujundžić, Renata.

DMM Latest Articles

This site uses cookies.

Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.